SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT01351324

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Acute Elevation of Non-esterified Fatty Acids on Endothelial Function and Insulin Sensitivity: A Comparison of Saturated and Long Chain n-3 Polyunsaturated Fatty Acids During the Postprandial Phase

Experimental elevation of non-esterified fatty acids (NEFA) impairs endothelial function and insulin sensitivity but the impact of NEFA composition is unknown. The objective was to test the effect of acute elevation of NEFA enriched with either saturated fatty acids (SFA) or SFA with long-chain n-3 polyunsaturated fatty acids (LC n-3 PUFA) on postprandial vascular function measured via flow-mediated dilatation (FMD), laser Doppler iontophoresis (LDI) and digital volume pulse (DVP), followed by a hyperinsulinaemic-euglycaemic clamp as a measure of whole body insulin sensitivity.

NCT01351324 Cardiovascular Risk Factors
MeSH: Insulin Resistance
HPO: Insulin resistance

1 Interventions

Name: Absence or presence of fish oil

Description: Oral dose of saturated fat with or without fish oil and a heparin infusion

Type: Dietary Supplement

SFA SFA + LC n-3 PUFA


Primary Outcomes

Measure: Flow-mediated dilatation

Time: Change from baseline to 240 min

Measure: Flow-mediated dilatation

Time: Change from 240 min to 390 min

Secondary Outcomes

Measure: Digital volume pulse

Time: Change from baseline to 240 min

Measure: Laser Doppler iontophoresis

Time: Change from baseline to 240 min

Measure: Insulin sensitivity

Time: 390 min

Measure: NEFA composition

Time: Change from baseline to 240 min

Measure: Circulating endothelial function markers

Time: Change from baseline to 240 min

Measure: Digital volume pulse

Time: Change from 240 min to 390 min

Measure: Laser Doppler iontophoresis

Time: Change from 240 min to 390 min

Measure: Circulating endothelial markers

Time: Change from 240 min to 390 min

Purpose: Basic Science

Allocation: Randomized

Crossover Assignment


There is one SNP

SNPs


1 E298D

Inclusion Criteria: - Healthy - Either homozygous for eNOS Glu298 (wildtype)or eNOS Asp298 (variant) Exclusion Criteria: - Smokers - Raised fasting blood lipids - Taking excessive fish oil supplements (>1g EPA/DHA per day) - Taking medication known to influence blood lipids, blood pressure or blood clotting Inclusion Criteria: - Healthy - Either homozygous for eNOS Glu298 (wildtype)or eNOS Asp298 (variant) Exclusion Criteria: - Smokers - Raised fasting blood lipids - Taking excessive fish oil supplements (>1g EPA/DHA per day) - Taking medication known to influence blood lipids, blood pressure or blood clotting Cardiovascular Risk Factors Insulin Resistance To investigate potential diet-gene interactions, potential subjects (n=370) were prospectively genotyped for the eNOS Glu298Asp polymorphism, of which 35 were Asp298 and 150 were Glu298 homozygotes. --- Glu298Asp ---



HPO Nodes


HPO:
Insulin resistance
Genes 122
LIPC KCNJ11 HNF1A GCGR STAT3 BSCL2 HSD3B2 ABCC8 AGPAT2 INS LMNA LMNB2 LMNA PDX1 ABCC8 ABCC8 INS CAV1 FOS ZMPSTE24 LMNA HYMAI LIPE BSCL2 CIDEC PLIN1 PPARG HYMAI CAV1 XRCC4 ADCY3 SLC2A2 CEP19 IGFALS LMNA MAPK8IP1 TCF7L2 DBH NEUROD1 NSMCE2 AKT2 PPARG XRCC4 IGF1 GATA6 NEUROD1 GCK AKT2 POLD1 PAX4 BSCL2 ALMS1 LMNA PDX1 PMM2 KCNJ11 HNF1A PTF1A HYMAI PLAGL1 HNF1B KLF11 NSMCE2 PIK3R1 BLK LIPE KCNJ11 GPD2 HMGA1 CEL INSR INSR ZFP57 CAV1 LEP ABCC8 SLC12A3 SLC30A8 EIF2AK3 LMNA GCK PDX1 RETN PDX1 CAVIN1 HNF4A IRS1 PIK3R1 ZFP57 PLAGL1 LEPR KCNJ11 ZMPSTE24 GCK MFN2 WFS1 ALMS1 APPL1 DCAF17 ABCC8 PAX4 ZMPSTE24 HSD11B1 AGPAT2 ENPP1 IRS2 HNF4A WRN PTPN1 PPP1R3A LMNA PAX4 PPARG IGF2BP2 KCNJ11 LMNA MTNR1B CLCNKB PPARG CAVIN1 EIF2AK3 CYP19A1